BD Claims Influenza Detection Test Meets FDA's New Performance Requirements

February 22, 2017

New Jersey–based BD (Becton, Dickinson and Company) says its BD Veritor system flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new FDA performance requirements introduced when the agency reclassified rapid flu tests from Class I to Class II.

The shift from Class I to Class II devices was prompted by the failure of some point-of-care flu tests during the 2009 pandemic. — Cynthia Jessup

View today's stories